Re-expression of CAMK2N1 in prostate cancer may provide clinical benefits to patients; however, further studies are warranted to determine the molecular mechanisms link between CAMK2N1 and androgen receptor signaling in prostate cancer. This evidence concerns the gene CAMK2N1 and prostate cancer.